Search Results - "Gressin, R."

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network by Soussain, C., Choquet, S., Blonski, M., Leclercq, D., Houillier, C., Rezai, K., Bijou, F., Houot, R., Boyle, E., Gressin, R., Nicolas-Virelizier, E., Barrie, M., Moluçon-Chabrot, C., Lelez, M.L., Clavert, A., Coisy, S., Leruez, S., Touitou, V., Cassoux, N., Daniau, M., Ertault de la Bretonnière, M., El Yamani, A., Ghesquières, H., Hoang-Xuan, K.

“…Primary central nervous system lymphomas (PCNSLs) are mainly diffuse large B-cell lymphomas (DLBCLs) of the non-germinal centre B-cell subtype, with unmet…”
Get full text

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA) by Ghesquieres, H., Chevrier, M., Laadhari, M., Chinot, O., Choquet, S., Moluçon-Chabrot, C., Beauchesne, P., Gressin, R., Morschhauser, F., Schmitt, A., Gyan, E., Hoang-Xuan, K., Nicolas-Virelizier, E., Cassoux, N., Touitou, V., Le Garff-Tavernier, M., Savignoni, A., Turbiez, I., Soumelis, V., Houillier, C., Soussain, C.

“…Primary central nervous system lymphomas (PCNSLs) are mainly diffuse large B-cell lymphomas (DLBCLs) of the non-germinal center B-cell (non-GCB) subtype. This…”
Get full text

Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers by Fossard, G., Broussais, F., Coelho, I., Bailly, S., Nicolas-Virelizier, E., Toussaint, E., Lancesseur, C., Le Bras, F., Willems, E., Tchernonog, E., Chalopin, T., Delarue, R., Gressin, R., Chauchet, A., Gyan, E., Cartron, G., Bonnet, C., Haioun, C., Damaj, G., Gaulard, P., Fornecker, L., Ghesquières, H., Tournilhac, O., da Silva, M. Gomes, Bouabdallah, R., Salles, G., Bachy, E.

“…Peripheral T-cell lymphoma (PTCL) remains a therapeutic challenge. Due to the rarity and the heterogeneity of PTCL, no consensus has been achieved regarding…”
Get full text

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial by Rossille, D, Gressier, M, Damotte, D, Maucort-Boulch, D, Pangault, C, Semana, G, Le Gouill, S, Haioun, C, Tarte, K, Lamy, T, Milpied, N, Fest, T

“…The dosage of soluble programmed cell death ligand 1 (sPD-L1) protein in the blood of adults with cancer has never been performed in a prospective patient…”
Get full text

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study by Dufour, J., Choquet, S., Hoang-Xuan, K., Schmitt, A., Ahle, G., Houot, R., Taillandier, L., Gressin, R., Casasnovas, O., Marolleau, J.P., Tamburini, J., Serrier, C., Perez, E., Paillassa, J., Gyan, E., Chauchet, A., Ursu, R., Kas, A., Soussain, C., Houillier, C.

“…Primary central nervous system lymphomas (PCNSLs) classically remain confined within the CNS throughout their evolution for unknown reasons. Our objective was…”
Get full text

Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’: [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723] by Fossard, G., Broussais, F., Coelho, I., Bailly, S., Nicolas-Virelizier, E., Toussaint, E., Lancesseur, C., Le Bras, F., Willems, E., Tchernonog, E., Chalopin, T., Delarue, R., Gressin, R., Chauchet, A., Gyan, E., Cartron, G., Bonnet, C., Haioun, C., Damaj, G., Gaulard, P., Fornecker, L., Ghesquières, H., Tournilhac, O., Gomesda Silva, M., Bouabdallah, R., Salles, G., Bachy, E.

Get full text

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review by Damaj, G, Cornillon, J, Bouabdallah, K, Gressin, R, Vigouroux, S, Gastinne, T, Ranchon, F, Ghésquières, H, Salles, G, Yakoub-Agha, I, Gyan, E

“…High-dose chemotherapy preceding autologous hematopoietic stem cell transplantation (auto-HSCT) is one treatment option for patients with Hodgkin (HL) or…”
Get full text

Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial by Tabouret, Emeline, Houillier, Caroline, Martin-Duverneuil, Nadine, Blonski, Marie, Soussain, Carole, Ghesquières, Herve, Houot, Roch, Larrieu, Delphine, Soubeyran, Pierre, Gressin, Remy, Gyan, Emmanuel, Chinot, Olivier, Taillandier, Luc, Choquet, Sylvain, Alentorn, Agusti, Leclercq, Delphine, Omuro, Antonio, Tanguy, Marie-Laure, Hoang-Xuan, Khe

“…Our aim was to review MRI characteristics of patients with primary CNS lymphoma (PCNSL) enrolled in a randomized phase II trial and to evaluate their potential…”
Get full text

Cell‐free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study by Sako, N., Delfau, M., Bachy, E., Morschhauser, F., Cartron, G., Casasnovas, O., Gressin, R., Daguindau, N., Tournilhac, O., Bouabdallah, K., Le Gouill, S., Andre, M., Robe, C., Dupuis, J., Leval, L., Gaulard, P., Lemonnier, F.

Get full text

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study by Bommier, C, Donzel, M, Rossi, C, Fornecker, L M, Bijou, F, Chauchet, A, Lebras, L, Ysabaert, L, Haioun, C, Bouabdallah, K, Gastinne, T, Morineau, N, Amorim, S, Jardin, F, Abraham, J, Lamy de la Chapelle, T, Gressin, R, Fouillet, L, Fruchart, C, Olivier, G, Morschhauser, F, Cherblanc, F, Belot, A, Le Guyader, S, Monnereau, A, Ghesquieres, H, Thieblemont, C

“…Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited…”
Get full text

RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY by Thieblemont, C., Lamy, T., Tani, M., Krzisch, D., Reda, G., Tedeschi, A., Usai, S. V., Guarini, A., Bijou, F., Stathis, A., Anastasia, A., Devizzi, L., Luminari, S., Arcaini, L., Casasnovas, O., Gressin, R., André, M., Houot, R., Bonomini, L., Zucca, E., Conconi, A.

Get full text

REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort by Bommier, C., Donzel, M., Rossi, C., Fornecker, L., Bijou, F., Chauchet, A., Lebras, L., Ysebaert, L., Haioun, C., Bouabdallah, K., Morineau, N., Gastinne, T., Amorim, S., Jardin, F., Abraham, J., Lamy de la Chapelle, T., Gressin, R., Fouillet, L., Fruchart, C., Morschhauser, F., Olivier, G., Cherblanc, F., Belot, A., Le Guyader, S., Monnereau, A., Ghesquières, H., Thieblemont, C.

Get full text

VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY by Sarkozy, C., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Damaj, G., Gastine, T., Ribrag, V., Casasnovas, O., Haioun, C., Houot, R., Jardin, F., Neste, E., Cheminant, M., Morschhauser, F., Callana, M., Ghesquieres, H., Gressin, R., Hermine, O., Le Gouill, S.

Get full text

CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HELPER T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY by Loyaux, R., Sako, N., Quang, V. Tran, Bachy, E., Morschhauser, F., Cartron, G., Gressin, R., Daguindau, N., Le Gouill, S., Wolfromm, A., Bouabdallah, K., Ysebaert, L., Casasnovas, O., Robe, C., Delfau, M., Dupuis, J., Leval, L., Gaulard, P., Sloma, I., Lemonnier, F.

Get full text

L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature by Jaccard, A., Petit, B., Girault, S., Suarez, F., Gressin, R., Zini, J.-M., Coiteux, V., Larroche, C., Devidas, A., Thiéblemont, C., Gaulard, P., Marin, B., Gachard, N., Bordessoule, D., Hermine, O.

“…Background: Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are highly aggressive diseases with a poor outcome…”
Get full text

A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial by Mozas, P., Ammar, R. Ould, Chartier, L., Nastoupil, L., Bachy, E., Bezsera, S. M., Barnes, J., Bijou, F., Goy, A., Zerazhi, H., Cartron, G., Ojeda‐Uribe, M., Choquet, S., Joly, B., Cheminant, M., García‐Sancho, A. Martín, Eradat, H., Gressin, R., Abrisqueta, P., Parcelier, A., Salazar, M. J. Rodríguez, Bonnet, C., Crump, M., López‐Guillermo, A., Morschhauser, F.

Get full text

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS by Houot, R., Le Gouill, S., Ojeda Uribe, M., Mounier, C., Courby, S., Dartigeas, C., Bouabdallah, K., Alexis Vigier, M., Moles, M.P., Tournilhac, O., Arakelyan, N., Rodon, P., El Yamani, A., Sutton, L., Fornecker, L., Assouline, D., Harousseau, J.L., Maisonneuve, H., Caulet-Maugendre, S., Gressin, R.

“…There is no consensual first-line chemotherapy for elderly patients with mantle cell lymphoma (MCL). The GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et…”
Get full text

Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study by LE GOUILL, Steven, DE GUIBERT, Sophie, FRUCHART, Christophe, DECONINCK, Eric, FITOUSSI, Olivier, GASTAUD, Lauris, DELWAIL, Vincent, GABARRE, Jean, GRESSIN, Rémy, BLANC, Michel, FOUSSARD, Charles, SALLES, Gilles, PLANCHE, Lucie, BRICE, Pauline, DUPUIS, Jehan, CARTRON, Guillaume, VAN HOOF, Achiel, CASASNOVAS, Olivier, GYAN, Emmanuel, TILLY, Hervé

“…We analyzed detailed characteristics and salvage treatment in 175 follicular lymphoma patients from the FL2000 study who were in progression after first-line…”
Get full text

Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group by Carras, S., Torroja, A., Emadali, A., Daguindau, N., Tempescul, A., Macro, M., Moreau, A., Tchernonog, E., Houot, R., Schmitt, A., Dartigeas, C., Dupuis, J., Jardin, F., Banos, A., Corm, S., Barbieux, S., Zerazhi, H., Arkam, Y., Fouillet, L., Fontan, J., Vilque, J., Moles, M., Sarkozy, C., Morineau, N., Joly, B., Voillat, L., Alexis, M., Fornecker, L. M., Garidi, R., Amorim, S., Bouabdallah, K., Dorvaux, V., Chabrot, C., Feugier, P., Damaj, G., Fleury, J., Delwail, V., Ysebaert, L., Burroni, B., Callanan, M., Legouill, S., Gressin, R.

Get full text

HIGH‐RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDY by Cheminant, M., Burroni, B., Le Bris, Y., Chartier, L., Oberic, L., Ribrag, V., Delfau, M.‐H., Thieblemont, C., Gressin, R., Canioni, D., Peyre, M., Laurent, C., Steimle, T., Kaltenbach, S., Asnafi, V., Macintyre, E., Callanan, M., Le Gouill, S., Hermine, O.

Get full text